PLASMABLASTIC LYMPHOMA
Clinical trials for PLASMABLASTIC LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new PLASMABLASTIC LYMPHOMA trials appear
Sign up with your email to follow new studies for PLASMABLASTIC LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Gene therapy takes on HIV and cancer in one shot
Disease control OngoingThis early-phase trial tests a gene therapy approach for people with HIV who also have lymphoma that has returned or not responded to treatment. Researchers take the patient's own stem cells, add anti-HIV genes in the lab, and return them after a stem cell transplant. The goal is…
Matched conditions: PLASMABLASTIC LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: AIDS Malignancy Consortium • Aim: Disease control
Last updated Jun 23, 2026 11:59 UTC
-
New immunotherapy combo aims to outsmart tough lymphomas
Disease control OngoingThis study is for people with aggressive B-cell lymphomas that have returned or not responded to standard treatments. It tests whether adding varlilumab to nivolumab (both drugs that help the immune system fight cancer) works better than nivolumab alone. About 54 participants wil…
Matched conditions: PLASMABLASTIC LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 18, 2026 11:49 UTC
-
Immunotherapy drug tested for rare blood cancers
Disease control TerminatedThis study tests the drug pembrolizumab in people with certain aggressive lymphomas or rare histiocyte/dendritic cell cancers that have come back or not responded to treatment. The goal is to see if the drug can shrink tumors. The study is currently suspended and enrolled 18 part…
Matched conditions: PLASMABLASTIC LYMPHOMA
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 18, 2026 11:48 UTC
-
Experimental drug shows promise for Tough-to-Treat lymphoma
Disease control OngoingThis study tests a drug called CPI-613 in people with relapsed or hard-to-treat Burkitt lymphoma or high-grade B-cell lymphoma. About 24 participants aged 12 and older who have not responded to at least one prior treatment will receive the drug. The goal is to see if the drug can…
Matched conditions: PLASMABLASTIC LYMPHOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 17, 2026 12:07 UTC